Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Mar 10, 2021
Neuren successfully completes manufacturing for Phase 2
Feb 24, 2021
Neuren corporate presentation, 24 February 2021
Feb 24, 2021
Neuren approaching transforming milestones in 2021
Feb 24, 2021
Preliminary Final Report and 2020 full year accounts
Feb 18, 2021
Change of Director's Interest Notice
Feb 17, 2021
Notification of investor briefing webinar
Feb 16, 2021
Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline
Feb 15, 2021
Successful Phase 1 trial for Neuren's NNZ-2591
Jan 29, 2021
Quarterly report and cash flow statement for Q4 2020
Jan 11, 2021
European Commission grants 3 NNZ-2591 Orphan designations
Previous
1
2
3
4
5
6